Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats  by Lange, Claudia et al.
Kidney International, Vol. 68 (2005), pp. 1613–1617
Administered mesenchymal stem cells enhance recovery from
ischemia/reperfusion–induced acute renal failure in rats
CLAUDIA LANGE,1 FLORIAN TO¨GEL,1 HARALD ITTRICH, FREDERIC CLAYTON, CLAUS
NOLTE-ERNSTING, AXEL R. ZANDER, and CHRISTOF WESTENFELDER
Department of Bone Marrow Transplantation, University of Hamburg, Hamburg, Germany; Department of Radiology, University
of Hamburg, Hamburg, Germany; Department of Medicine, Division of Nephrology, University of Utah, Salt Lake City, Utah;
Department of Pathology, University of Utah, Salt Lake City, Utah; and Department of Physiology, University of Utah, Salt Lake
City, Utah; VA Medical Center, Salt Lake City, Utah
Mesenchymal stem cells are renoprotective in ischemia/
reperfusion-induced acute renal failure in rats.
Background. Adult stem cells are promising for the develop-
ment of novel therapies in regenerative medicine. Acute renal
failure (ARF) remains a frequent clinical complication, associ-
ated with an unacceptably high mortality rate, in large part due
to the ineffectiveness of currently available therapies. The aim
of this study was, therefore, to evaluate the therapeutic effec-
tiveness of bone marrow–derived mesenchymal stem cells in a
rat model of ischemia/reperfusion (I/R) ARF.
Methods. We used a common I/R model in rats to induce ARF
by clamping both renal pedicles for 40 minutes. Mesenchymal
stem cells were iron-dextran–labeled for in vivo tracking stud-
ies by magnetic resonance imaging (MRI) and kidneys were
imaged for mesenchymal stem cells immediately after infusion
and at day 3 after ARF. Renal injury was scored on day 3 and
cells were additionally tracked by Prussian blue staining.
Results. We show in I/R-induced ARF in rats, modeling the
most common form of clinical ARF, that infusion of mesenchy-
mal stem cells enhances recovery of renal function. Mesenchy-
mal stem cells were found to be located in the kidney cortex
after injection, as demonstrated by MRI. Mesenchymal stem
cells–treated animals had both significantly better renal func-
tion on days 2 and 3 and better injury scores at day 3 after ARF.
Histologically, mesenchymal stem cells were predominantly lo-
cated in glomerular capillaries, while tubules showed no iron
labeling, indicating absent tubular transdifferentiation.
Conclusion. We conclude that the highly renoprotective ca-
pacity of mesenchymal stem cells opens the possibility for a
cell-based paradigm shift in the treatment of I/R ARF.
Ischemic acute renal failure (ARF), characterized by
a sharp decline of glomerular filtration rate (GFR), is a
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very common complication in hospitalized patients and
particularly in patients with multiorgan failure. Although
it develops most frequently in multimorbid patients, its
occurrence per se increases the risk of death by 10- to 15-
fold [1]. This unacceptable situation warrants the urgent
development of new treatment modalities.
Theoretically, cell-based therapies may have the ad-
vantage of acting through multiple mechanisms in disor-
ders with highly complex pathophysiology, such as ARF,
while pharmacologic interventions often target only a sin-
gle aspect of a disease. In the pathophysiology of ARF,
components of vascular [2], inflammatory [3], and tubu-
lar injury [4] have been identified. Due to this complexity,
it is thought that ARF may be an ideal target for a cell
therapeutic approach.
Bone marrow–derived hematopoietic stem cells have
been discovered to transdifferentiate into cells of differ-
ent germ layers [5]. Physiologically, mesenchymal stem
cells give rise to osteocytes, chondrocytes, and adipocytes,
but were recently found to differentiate into endothelial,
myocardial [6], liver [7], renal [8], and pulmonary ep-
ithelial cells [9]. Mesenchymal stem cells have also been
shown to have immunomodulatory capabilities [10], and
express growth factors known to be renoprotective in ex-
perimental ARF [11].
Based on this background, the objective of the present
study was to test the therapeutic potential of mesenchy-
mal stem cells, administered to rats following induction of
ARF by ischemia/reperfusion (I/R), and to monitor their
physical presence in the injured kidney using magnetic
resonance imaging (MRI) and histology.
METHODS
All animal work was approved by the Institutional
Animal Control and Utilization Committee. I/R ARF
was induced in anesthetized (ketamine/xylazine), adult
male Sprague-Dawley rats, weighing 300 to 400g
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(mesenchymal stem cells–treated group, N = 7) (con-
trol group, N = 6) by clamping both renal pedicles for
40 minutes. Reflow was visually confirmed, and, to re-
duce abdominal air, 4 mL warm normal saline was given
intraperitoneally before abdominal closure.
Rat mesenchymal stem cells were generated from the
bone marrow of adult Sprague-Dawley rats by standard
procedures [12, 13]. Their phenotype and purity were con-
firmed by their ability to differentiate into adipocytes,
chondrocytes and osteocytes as well as exclusion, by
fluorescence-activated cell sorter (FACS) analysis, of
contaminating CD45-positive cells, respectively. Further-
more, mesenchymal stem cells used in this study were
cultured for more than 10 passages, which practically ex-
cludes hematopoietic cell contamination. Cultured mes-
enchymal stem cells were prelabeled for 24 hours with
carboxy-dextran-coated iron oxide nanoparticles (Reso-
vist) (Schering, Berlin, Germany), diluted 1:30 in me-
dia. Before trypsinization mesenchymal stem cells were
washed with phosphate-buffered saline (PBS) to elimi-
nate extracellular iron-dextran. After reflow, 1.5 × 106
mesenchymal stem cells in 1 mL of normal saline were
infused into the thoracic aorta via a carotid artery, con-
trols received vehicle. Renal function was monitored by
measurement of serum creatinine and blood urea nitro-
gen (BUN), using an autoanalyzer. The serum creati-
nine levels obtained in this fashion were confirmed by
high-performance liquid chromatography (HPLC) (data
not shown) and found to be identical. At 72 hours af-
ter ARF, animals in both groups were studied by MRI
for in vivo tracking of administered mesenchymal stem
cells, then sacrificed to obtain kidney injury scores and for
localization of administered mesenchymal stem cells. Se-
quential kidney sections were stained with hematoxylin
and eosin for injury scoring, with Prussian blue for track-
ing of iron-loaded mesenchymal stem cells, and double-
stained for CD68 (immunohistochemistry) and Prussian
blue to identify infiltrating macrophages that may be
iron-positive. The kidneys were formalin-fixed and
paraffin-embedded and 4 l thick periodic acid-Schiff
(PAS)–stained sections were scored by a standard
method as previously reported [14, 16], and addition-
ally examined for disruption or loss of the tubular brush
border as a measure of tubular injury. Lines were drawn
on the slides perpendicular to the cortical surface, and
contiguous high power fields (0.41 mm diameter) were
examined along these lines from the cortical surface to
the medulla (the first field containing no glomeruli). This
was done to assure a representative sampling of different
parts of the cortex, since the injury was inhomogeneous
and more severe in the deep cortex. The mean number of
disrupted, markedly attenuated, or missing tubular brush
borders per field were counted in a blinded fashion on
coded slides. A minimum of 16 fields of each kidney were
examined.
Data are expressed as means ± SD. Differences
between data means were analyzed by analysis of vari-
ance (ANOVA) or Student t test using Prism software
(GraphPad, San Diego, CA, USA). A P value of less
than 0.05 was considered significant.
RESULTS
Iron-dextran incubation resulted in effective labeling
of mesenchymal stem cells (Fig. 1A and B). Forty minutes
of ischemia led to severe renal damage in control ARF
animals, causing significant increases in serum creatinine
levels (Fig. 1C) from a common baseline for both groups
of 0.48 ± 0.13 mg/dL to 2.3 ± 0.3 mg/dL, 4.0 ± 1.1 mg/dL,
and 2.7 ± 1.0 mg/dL at days 1, 2, and 3, respectively (Fig.
1C). Animals with ARF who received mesenchymal stem
cells immediately post-reflow had a significantly better
renal function on days 2 and 3 after ARF (Fig. 1C). Serum
creatinine on day 1 was 2.4 ± 0.3 mg/dL, on day 2, 2.2 ± 1.1
mg/dL, and on day 3, 1.3 ± 0.7 mg/dL). Obtained serum
creatinine data were qualitatively paralleled by changes
in BUN levels (not shown), thereby further validating
the utility of using serum creatinine as a marker of renal
function in rats.
MRI 30 to 120 minutes after reflow showed loss of outer
renocortical signal, consistent with the presence of iron-
labeled mesenchymal stem cells in the kidney (Fig. 2A
and B). This pattern persisted in all mesenchymal stem
cells–treated rats until day 3, together suggesting the con-
tinued intrarenal presence of injected mesenchymal stem
cells during this observation period. At no time point did
infusion of free iron-dextran particles after ARF result in
changes in kidney signal intensity (not shown), thereby
excluding significant intrarenal accumulation of free iron-
dextran. Further details of the MRI data will be reported
elsewhere (manuscript in preparation).
Histologically, on day 3, iron-labeled mesenchymal
stem cells of characteristic phenotype (Fig. 1) were found
predominantly in glomerular capillaries (Fig. 2C to E) at
a frequency of 2 to 32 (average 17.6 cells per section)
or approximately 30,000 cells per kidney, as calculated
by volume, together corresponding well with the signal
extinction observed on MRI. The ratio of cells found in
glomeruli versus interstitial locations was 1.1. Mononu-
clear cell infiltration peaks at days 3 to 5 following is-
chemic ARF. As we did not detect a signal loss on MRI
or iron staining (Fig. 2E) in animals injected with free
iron-dextran only, it is unlikely that the signal in the
kidneys is derived from infiltrating monocytes that have
phagocytozed contrast material [15]. This possibility was
further excluded by double-staining kidneys for CD68
and with Prussian blue, both of which failed to detect
any iron-loaded macrophages (Fig. 2E). Renal injury was
scored (0, intact kidney; 300, cortical necrosis) in all an-
imals in blinded fashion by a standard method [14, 16].
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Fig. 1. Mesenchymal rat stems cells show ef-
ficient uptake and endosomal accumulation
of super paramagnetic particles of iron ox-
ide (SPIO) (A) in comparison to nonlabeled
cells (B) (original magnification 200×, Prus-
sian blue stain). The observed differences in
nuclear and cell sizes are well known to exist in
culture expanded, essentially pure mesenchy-
mal stem cell populations [12]. (C) Serum cre-
atinine (mean ± SD) at baseline and days 1, 2,
and 3 after acute renal failure (ARF) in con-
trol animals () (N = 6), and in mesenchymal
stem cells–treated animals () (N = 7). Mes-
enchymal stem cell treatment led to a signif-
icant improvement in renal function on days
two and three after ARF, as determined by t
test.
Mesenchymal stem cells–treated animals had a signifi-
cantly lower (P = 0.03) injury score of 23 ± 4 compared
to that of 88 ± 46 in controls.
Additionally, assessing brush border preservation in
proximal tubules, a highly sensitive marker for surviv-
ing, functional proximal tubular cells (i.e., the site where
injury due to I/R is most intense) showed on day 3 in mes-
enchymal stem cells–treated animals 47 ± 5.9% preser-
vation of proximal tubular brush border was preserved
and only 33 ± 7.4% in control animals (P = 0.019).
DISCUSSION
Labeling of cells with iron-dextran has been shown to
be a nontoxic and long-lasting method for in vivo track-
ing of cells, including stem cells [17–19], as was shown in
myocardial infarction models in which labeled mesenchy-
mal stem cells were directly injected into the myocardium
[20, 21]. In addition, their canonical ability to differentiate
into adipocytes and osteocytes is preserved. Mesenchy-
mal stem cells have also been shown to enhance recovery
after myocardial infarction through mechanisms other
than transdifferentiation into myocytes [6], and they were
found to promote angiogenesis through paracrine mech-
anisms [22].
We demonstrate here that iron-dextran labeled
mesenchymal stem cells injected after ARF can be histo-
logically located in the kidney, significantly enhance the
recovery of renal function, and that they can be tracked
in the kidney using MRI. Because of the absence of iron-
stained tubules and vascular endothelial cells, the mostly
glomerular location of labeled mesenchymal stem cells,
and their early effects on improving renal function on
days 2 and 3, we hypothesize that transdifferentiation of
administered mesenchymal stem cells into renal cells, a
process that requires more than 3 days, is not their pri-
mary renoprotective mechanism. Whether the prolonged
presence of mesenchymal stem cells in glomeruli is the re-
sult of specific homing or random entrapment remains to
be elucidated. Whatever the mechanism for the localiza-
tion of mesenchymal stem cells in the kidney turns out to
be, the administration of mesenchymal stem cells in rats
with ARF is associated with a faster recovery of renal
function. In a cisplatinum model of renal failure, occa-
sional transdifferentiation of administered mesenchymal
stem cells into tubular cells was observed 28 days after
cell infusion [8]. However, it is unclear if this mecha-
nism contributed significantly to the renoprotection that
was seen much earlier in the course of this toxic form of
ARF (i.e., at a time when the authors did not quantitate
the frequency of transdifferentiation events) [8]. In fur-
ther support of our hypothesis that the obtained early
recovery is affected by transdifferentiation-independent
mechanisms are data reported using vascular endothe-
lial cells and muscle-derived stem cells. In these,
renoprotection in ARF was mediated by nitric ox-
ide release and other transdifferentiation-independent
mechanism [23, 24]. However, the exact mechanisms
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Fig. 2. Homing and tracking of iron-dextran–labeled mesenchymal stem cells in the kidney. Animals were anesthetized and coronal T2-weighted
gradient echo in vivo magnetic resonance images (MRI) were obtained before (A), and after injection of magnetically labeled (iron-dextran),
syngeneic mesenchymal stem cells (B and C). (D) Iron-labeled cells can be located in the glomeruli (original magnification 40×, Prussian blue
stain). (E) Double staining of normal spleen with CD68 and Prussian blue (positive control). (F) Double staining of kidney with CD68 and
Prussian blue shows absence of staining of iron-labeled cells, indicating that iron-stained cells are not macrophages. (G) Vehicle-treated kidney
shows extensive tubular damage and inflammatory cell infiltration. (H) Mesenchymal stem cells–treated kidney shows better preserved tubular
architecture and only mild damage.
underlying the better organ recovery of kidneys treated
with mesenchymal stem cells in I/R ARF remain to be
investigated.
In summary, we have shown that adult bone marow–
derived mesenchymal stem cells can be detected in the
kidney after I/R-induced ARF, and that they significantly
enhance the recovery after renal failure by mechanisms
distinct from transdifferentiation into renal tubular or
vascular endothelial cells. We conclude that their ro-
bust renoprotective actions, likely mediated by various
paracrine mechanisms, have substantial promise for the
development of a novel, cell-based approach to the
treatment of clinical ARF. In this fashion, we suggest,
vascular, inflammatory and tubular injury components
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of this largely treatment resistant complication can be
simultaneously targeted. Since mesenchymal stem cells
can be readily obtained from a patient at high risk for or
with established ARF, and since they can be efficiently
culture expanded, purified, and administered prophylac-
tically or therapeutically, their use in clinical ARF may be
most practical. Finally, the ease with which mesenchymal
stem cells can be iron-dextran labeled and monitored by
MRI in vivo provides a useful and safe tool to monitor
the renal presence of administered mesenchymal stem
cells and allows for the in vivo correlation of obtained
renoprotection with the quality and duration of renal sig-
nal extinction by a given number of administered mes-
enchymal stem cells (i.e., providing a measure whereby
the renoprotective effectiveness of a single or repeated
cell dose can be gauged).
CONCLUSION
Our results demonstrate the effects of mesenchymal
stem cells on enhanced recovery of renal function in I/R
ARF and provide the basis for a new therapeutic concept
for the treatment of ARF.
NOTE ADDED IN PROOF
Using 2 photon laser confocal microscopy and Y-
chromosome FISH, we recently confirmed that the reno-
protective actions of mesenchymal stem cells in acute re-
nal failure are mediated by differentiation-independent
mechanisms (Am J Physiol Renal Physiol 289:F31–F42,
2005).
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